Company Email Format Management

Cyclerion

Biotechnology Research Cambridge, Ma, United States 12 employees

Employees: 12
Contacts: 3
Emails: 3

www.cyclerion.com LinkedIn Crunchbase

Cyclerion Overview

Headquarters: Cambridge, Ma, United States
Website: www.cyclerion.com
Industry: Biotechnology Research
Employees: 12
Founded: 2019
Funding: 5.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Manager jobs

About Cyclerion

Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.

Cyclerion Contact Details

People in AeroLeads: 3
With contact data: 3
Email contacts: 3; 100.0% coverage

Cyclerion Org Chart

Sample employees and titles

Name	Title	Location	Contact
Kenneth Tripp	Head of Biostatistics, Cyclerion	Greater Boston, United States	Email
Mark Currie	Member Board of Directors at Sea	Greater Boston, United States	Email
Harry Hanson	Systems Support Analyst at Cyclerion	Greater Boston, United States	Email